Liver Fibrosis Market Poised for a CAGR of Approximately 24% Through 2034

The Liver Fibrosis market was valued at approximately USD 2.6 billion in 2025 and is projected to grow at a robust CAGR of approximately 24% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Liver Fibrosis landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Liver Fibrosis market is increasingly guided by biomarker-driven and metabolic-based treatment strategies. Metabolic dysfunction-associated steatohepatitis (MASH) represents a highly lucrative disease segment, highlighted by the landmark FDA approval of Rezdiffra (resmetirom) in March 2024. Currently, Rezdiffra stands as the only FDA-approved pharmacological treatment for patients with noncirrhotic MASH and moderate to advanced liver fibrosis, establishing a new standard of care and generating significant market momentum.

Liver fibrosis is a chronic condition characterized by excessive accumulation of collagen and other extracellular matrix components, resulting from persistent liver injury. This abnormal wound-healing response distorts the liver's architecture, potentially progressing to cirrhosis, portal hypertension, and ultimately liver failure. Previously classified as non-alcoholic fatty liver disease (NAFLD) and its more inflammatory form, non-alcoholic steatohepatitis (NASH), updated terminology now emphasizes metabolic dysfunction. Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), alongside other classifications such as MASL, NASL, and metabolic alcohol-related liver disease (MetALD), fall under the broader category of steatotic liver disease (SLD), offering improved diagnostic precision by emphasizing metabolic dysfunction.

DelveInsight's report, “Liver Fibrosis Market Insight, Epidemiology And Market Forecast - 2034,” estimated approximately 8 million diagnosed prevalent cases of liver fibrosis across the seven major markets (7MM) in 2024, with this figure expected to increase significantly by 2034. The condition affects populations globally, with prevalence varying across regions based on lifestyle factors, genetic predispositions, and healthcare access. The aging population, particularly individuals aged 65 and older, demonstrates higher rates of liver fibrosis diagnosis compared to younger cohorts, reflecting the disease's cumulative nature and extended progression timeline.

To know in detail about the Liver Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, visit Liver Fibrosis Market Forecast

Some of the Key Facts of the Liver Fibrosis Market Report

• Key Liver Fibrosis Companies: Madrigal Pharmaceuticals, Inventiva, Akero Therapeutics, Eli Lilly and Company, Boehringer Ingelheim, Zealand Pharma, Genzyme (Sanofi), Viking Therapeutics, Structure Therapeutics, Novartis, Roche, Gilead Sciences, and others.
• Key Liver Fibrosis Therapies: Rezdiffra (resmetirom), Lanifibranor, Efruxifermin, Denifanstat, Pegozafermin, Tirzepatide, Survodutide, Semaglutide, Belapectin, Vitamin E & Pioglitazone, and others.
• The Liver Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.

Liver Fibrosis Overview

Liver fibrosis is a progressively worsening condition marked by excessive collagen buildup resulting from ongoing liver damage. This abnormal wound-healing response distorts the liver's structure, potentially progressing to cirrhosis, portal hypertension, and ultimately liver failure. The disease encompasses multiple underlying etiologies, including viral hepatitis, alcoholic liver disease, metabolic dysfunction-associated fatty liver disease, and autoimmune conditions. Early detection through advanced diagnostic methodologies and personalized treatment approaches improve patient outcomes and may prevent or delay disease progression to advanced cirrhosis.

Get a Free sample of the Liver Fibrosis Market Report

Key Trends in Liver Fibrosis Therapeutics Market

• The shift in disease terminology from NASH to MASH reflects growing recognition of metabolic dysfunction as a central pathogenic mechanism, guiding therapeutic development toward metabolic targets and enabling more precise patient stratification.
• Thyroid Hormone Receptor-Beta Activation: Rezdiffra's mechanism of action through thyroid hormone receptor-beta (THR-β) activation represents a novel therapeutic approach, targeting underlying pathophysiology by promoting hepatic lipid metabolism and reducing fibrosis markers.
• Pan-PPAR Agonist Development: Lanifibranor's approach of activating multiple peroxisome proliferator-activated receptors (PPARs) addresses inflammation, fibrosis, and metabolic dysfunction simultaneously, offering a differentiated mechanism particularly valuable for patients with advanced fibrosis and type 2 diabetes comorbidity.
• GLP-1 and Glucagon Receptor Agonists: Tirzepatide and survodutide demonstrate preliminary positive results in Phase 2 clinical trials, leveraging metabolic regulation and glucagon signaling to address underlying disease mechanisms in liver fibrosis associated with metabolic dysfunction.
• Precision Medicine and Biomarker Testing: Enhanced molecular diagnostics and non-invasive biomarker testing enable earlier detection of liver fibrosis, stratification of patient populations by disease severity and underlying etiology, and monitoring of treatment response. Advanced plasma protein profiling and imaging modalities identify potential biomarkers, guiding personalized treatment strategies.
• Combination Therapeutic Approaches: Multi-targeted combination therapies address the complex pathophysiology of liver fibrosis through synergistic mechanisms, improving efficacy and potentially overcoming resistance patterns observed with monotherapies.

Liver Fibrosis Epidemiology

The report on Liver Fibrosis epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease severity segmentation according to fibrosis staging. The report highlights disease burden in the context of underlying etiologies such as MASH, hepatitis B and C, alcoholic liver disease, and autoimmune hepatitis, alongside projections for future trends. These epidemiological insights enable stakeholders to understand the scope of liver fibrosis and plan targeted interventions, research initiatives, and treatment strategies.

Liver Fibrosis Epidemiology Segmentation

The Liver Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Liver Fibrosis Diagnosed Prevalent Cases
• Liver Fibrosis Severity-specific Diagnosed Prevalent Cases
• Total Liver Fibrosis Diagnosed Prevalent Cases (≥F2 Stage) in MASH

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiology Forecast

Recent Developments in the Liver Fibrosis Treatment Landscape

• In August, 2025, the FDA approved WEGOVY (semaglutide), marketed by Novo Nordisk, for the treatment of MASH with moderate to advanced fibrosis. This approval was based on Phase 3 trial interim results showing improvement in liver inflammation, fibrosis, and MASH resolution.
• In March 2025, positive clinical trial developments for Belapectin, explored for NASH with cirrhosis, showed promise to address both fibrosis and inflammation.
• In July 2025, GSK completed the acquisition of Boston Pharmaceuticals for up to $2 billion, acquiring efimosfermin alfa, a Phase III-ready drug candidate for treating and preventing progression of steatotic liver disease (SLD), including liver fibrosis.
• In September 2025, Roche announced the acquisition of 89bio in a $3.5 billion deal. 89bio’s lead candidate focuses on NASH and severe hypertriglyceridemia, aiming to treat liver inflammation and fibrosis.
• In October 2024, the FDA granted Breakthrough Therapy Designation to Sagimet Biosciences for denifanstat (TVB-2640), an oral fatty acid synthase inhibitor, for noncirrhotic MASH patients with moderate to advanced fibrosis. Phase 2b trial data showed significant disease resolution without worsening fibrosis in patients treated with denifanstat versus placebo.
• In March 2024, the FDA granted accelerated approval to Rezdiffra (resmetirom) by Madrigal Pharmaceuticals for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3). This is the first FDA-approved drug specifically targeting MASH with liver fibrosis.

Liver Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Liver Fibrosis market or expected to be launched during the study period. The analysis covers Liver Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liver Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.

Liver Fibrosis Therapies and Key Companies

• Rezdiffra (resmetirom): Madrigal Pharmaceuticals
• Lanifibranor: Inventiva
• Efruxifermin: Akero Therapeutics
• Denifanstat: Denifanstat Sponsor (with BTD/FTD from FDA)
• Pegozafermin: Novo Nordisk
• Tirzepatide: Eli Lilly and Company
• Survodutide: Boehringer Ingelheim and Zealand Pharma
• Semaglutide: Novo Nordisk
• Belapectin: Galera Therapeutics

To know more about Liver Fibrosis companies working in the treatment market, visit @ Liver Fibrosis Clinical Trials and Therapeutic Assessment

Liver Fibrosis Market Drivers

• Increasing prevalence of liver fibrosis globally, driven by rising rates of metabolic dysfunction-associated fatty liver disease, hepatitis B and C infections, alcoholic liver disease, and autoimmune hepatitis
• FDA approval of Rezdiffra in March 2024, establishing the first pharmacological treatment option for MASH-associated fibrosis and catalyzing increased disease awareness and patient diagnosis.
• Advancements in molecular diagnostics and biomarker testing, enabling precision medicine approaches with early detection of liver fibrosis and stratification of patient populations by disease severity and underlying etiology.
• Robust clinical pipeline, with multiple therapies in Phase 2 and Phase 3 development demonstrating positive efficacy and safety signals, supporting anticipated near-term regulatory approvals.
• Rising healthcare expenditure and government initiatives, supporting cancer care and chronic disease management infrastructure expansion in major markets.
• Development of combination therapies, improving patient outcomes through synergistic mechanisms targeting multiple pathogenic pathways simultaneously.
• Growing awareness among healthcare providers and patients, regarding liver fibrosis risk factors, disease progression, and availability of novel therapeutic options.

Liver Fibrosis Market Barriers

• High cost of targeted therapies and emerging drug candidates, potentially limiting patient access and healthcare system adoption in resource-constrained regions.
• Complex clinical trial designs and lengthy regulatory approval processes, delaying market entry of innovative therapies and extending time-to-patients.
• Variability in disease presentation and underlying etiology, necessitating personalized treatment approaches and complicating standardization of clinical protocols.
• Limited awareness and accessibility in emerging markets, constraining disease diagnosis and treatment uptake in resource-limited healthcare systems.
• Side effects and safety concerns associated with some experimental therapies.
• Reimbursement and market access challenges, with healthcare payers requiring robust evidence of cost-effectiveness and long-term clinical benefit compared to standard care approaches.

Scope of the Liver Fibrosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Liver Fibrosis Companies: Madrigal Pharmaceuticals, Inventiva, Akero Therapeutics, Eli Lilly and Company, Boehringer Ingelheim, Zealand Pharma, Genzyme (Sanofi), Viking Therapeutics, Structure Therapeutics, Novartis, Roche, Gilead Sciences, and others
• Key Liver Fibrosis Therapies: Rezdiffra (resmetirom), Lanifibranor, Efruxifermin, Denifanstat, Pegozafermin, Tirzepatide, Survodutide, Semaglutide, Belapectin, Vitamin E & Pioglitazone, and others
• Liver Fibrosis Therapeutic Assessment: Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
• Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Liver Fibrosis Unmet Needs, KOL's views, Analyst's views, Liver Fibrosis Market Access and Reimbursement

Discover More About Therapies Set to Grab Major Liver Fibrosis Market Share @ Liver Fibrosis Treatment Market